PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
264.51%
Other expenses growth above 1.5x AVXL's 26.67%. Michael Burry would check for concerning trends.
3.15%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
3.15%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
-0.34%
Interest expense reduction while AVXL shows 66.35% growth. Joel Greenblatt would examine advantage.
-75.00%
D&A reduction while AVXL shows 26.67% growth. Joel Greenblatt would examine efficiency.
15.50%
EBITDA growth below 50% of AVXL's 75.41%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
16.24%
Operating income growth below 50% of AVXL's 52.11%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-3.90%
Other expenses reduction while AVXL shows 336.35% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Tax expense growth while AVXL reduces burden. John Neff would investigate differences.
12.65%
Net income growth below 50% of AVXL's 77.47%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
12.55%
EPS growth below 50% of AVXL's 77.53%. Michael Burry would check for structural issues.
12.55%
Diluted EPS growth below 50% of AVXL's 77.53%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.